
Press Release

August 31, 2026

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Selected as a Constituent of Five GPIF-Adopted ESG Indexes

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced today that it has been selected as a constituent of five ESG indexes covering Japanese equities adopted by the Government Pension Investment Fund (GPIF).

The Company was selected for inclusion in the five ESG indexes: the FTSE JPX Blossom Japan Index, the FTSE JPX Blossom Japan Sector Relative Index, the MSCI Nihonkabu ESG Select Leaders Index, the S&P/JPX Carbon Efficient Index, and Morningstar Japan ex-REIT Gender Diversity Tilt Index.

In addition to the above indexes adopted by GPIF, the Company has been selected for inclusion in the FTSE4Good Index Series, a leading ESG investment index.

Sumitomo Pharma Group defines the practice of its Mission, "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," that contributes to the realization of a sustainable society and leads to the sustained enhancement of its corporate value as "Sustainability Management." Sumitomo Pharma will continue to promote Sustainability Management.

* For information on Sumitomo Pharma's Sustainability Management initiatives and external evaluation, please visit: <https://www.sumitomo-pharma.com/sustainability>

(Reference)

About the five ESG indexes adopted by GPIF in which Sumitomo Pharma has been included

■ **FTSE JPX Blossom Japan Index**

The FTSE JPX Blossom Japan Index is an ESG index provided through a collaboration between FTSE Russell (U.K.) and Japan Exchange Group (JPX), and comprises Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices. Sumitomo Pharma has been continuously included as a constituent in the Index since 2017 when the Index was launched.

■ **FTSE JPX Blossom Japan Sector Relative Index**

Like the FTSE JPX Blossom Japan Index, the FTSE JPX Blossom Japan Sector Relative Index is composed of Japanese companies with relatively strong ESG practices that are evaluated relative to their peers within each sector. The Index is designed to reflect companies' ESG initiatives while reducing sector bias.

Sumitomo Pharma has been continuously included as a constituent in the Index since 2022 when the Index was launched.

■ **MSCI Nihonkabu ESG Select Leaders Index**

Among the stocks that make up the MSCI Nihonkabu IMI Index, the MSCI Nihonkabu ESG Select Leaders Index aims to represent the performance of companies that are leading within their GICS® sector groups in terms of ESG evaluations while also meeting certain quality factor criteria. Sumitomo Pharma has been continuously included as a constituent in the index since 2024 when the Index was launched.

■ **S&P/JPX Carbon Efficient Index**

The S&P/JPX Carbon Efficient Index is an ESG index jointly designed by S&P Dow Jones Indices and Japan Exchange Group. This index comprises companies included in the Tokyo Stock Price Index (TOPIX), and the constituent weights are determined by carbon efficiency (Carbon emissions per unit of revenue) and the disclosure status of environmental information. Sumitomo Pharma has been continuously included as a constituent in the Index since 2018 when the Index was launched.

■ **Morningstar Japan ex-REIT Gender Diversity Tilt Index**

Built with the data and scoring methodology of Equileap (Netherlands), the Morningstar (U.S.) Gender Diversity Indexes are designed to emphasize the stocks of companies that have strong gender diversity policies embedded in their corporate culture and that ensure equal opportunities to employees, irrespective of their gender. This index was newly adopted by GPIF from March 2023. Sumitomo Pharma has been continuously included as a constituent since its establishment in 2023.

About FTSE4Good Index Series

The FTSE4Good Index Series is created by the global index provider FTSE Russell (U.K.) to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. Transparent management and clearly defined ESG criteria make FTSE4Good indexes suitable tools to be used by a wide variety of market participants when creating or assessing sustainable investment products.

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp